Source: International Congress 2019 – The world of idiopathic pulmonary fibrosis
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
F. Caro (Buenos Aires, Argentina), I. Buendia Roldán (Mexico, Mexico), P. Curbelo (Montevideo, Uruguay), R. Kairalla (Sao Pablo, Brazil), M. Mejía (Mexico, Mexico), L. Noriega (Panamá City, Panama), F. Paulin (Buenos Aires, Argentina), A. Undurraga (Santiago, Chile), M. Selman (Mexico, Mexico), O. Refipi Group (Montevideo, Uruguay). Treatment of patients with idiopathic pulmonary fibrosis in real-life setting: Results from the Latin American Pulmonary Fibrosis Registry REFIPI. 1730

Member's Comments

No comment yet.

Related content which might interest you: The European IPF Registry: Addressing challenges and characteristics of patients with Idiopathic Pulmonary Fibrosis Source: International Congress 2018 – The world of idiopathic pulmonary fibrosis (IPF): global registries Year: 2018 The Latin American Idiopathic Pulmonary Fibrosis Registry (REFIPI): Baseline Characteristics Source: International Congress 2019 – Biomarkers of idiopathic interstitial pneumonia Year: 2019 Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry Source: Eur Respir J , 49 (2) 1601592; DOI: 10.1183/13993003.01592-2016 Year: 2017 Diagnosis, treatment and attitudes about idiopathic pulmonary fibrosis in Latin American physicians Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Pirfenidone in idiopathic pulmonary fibrosis - description of a German cohort Source: International Congress 2014 – ILDs 4 Year: 2014 Long-term survival analysis: Pirfenidone compared to standard care for the treatment of patients with idiopathic pulmonary fibrosis Source: International Congress 2014 – Clinical trials in IPF Year: 2014 Intraindividual response to treatment with pirfenidone in two independent European IPF cohorts Source: International Congress 2014 – ILDs 2 Year: 2014 Impact of treatment strategy in survival of patients with idiopathic pulmonary arterial hypertension. Real world evidence from Spanish National Pulmonary Hypertension Registry (REHAP) Source: International Congress 2018 – Pulmonary hypertension: therapy Year: 2018 Clinical outcomes of patients with idiopathic pulmonary fibrosis in clinical practice: Follow-up results of the INSIGHTS-IPF registry Source: International Congress 2015 – IPF: clinical aspects II Year: 2015 Combined pulmonary fibrosis and emphysema: A report from the Hellenic Interstitial Lung Diseases group Source: Annual Congress 2010 - Different patterns of interstitial lung disease Year: 2010 LATE-BREAKING ABSTRACT: Current management of patients with idiopathic pulmonary fibrosis in clinical practice: INSIGHTS-IPF registry Source: International Congress 2014 – Clinical trials in IPF Year: 2014 Registry of idiopathic pulmonary fibrosis patients Source: International Congress 2016 – Russia Session Year: 2016 The effect of pirfenidone with patients with idiopathic pulmonary fibrosis in one university hospital Source: International Congress 2014 – ILDs 4 Year: 2014 Effect of design modifications on trial outcomes in idiopathic pulmonary fibrosis (IPF): Analysis of data from ASCEND and CAPACITY (CAP) Source: International Congress 2014 – IPF and surroundings Year: 2014 LATE-BREAKING ABSTRACT: Efficacy of Pirfenidone for Idiopathic Pulmonary Fibrosis (IPF): an Italian real life study Source: International Congress 2014 – IPF and surroundings Year: 2014 Association between Pulmonary Infections and the Prognosis in Patients with Idiopathic Pulmonary Fibrosis Source: Virtual Congress 2021 – Interstitial lung disease around the world Year: 2021 PROOF-registry: A prospective observational registry to describe the disease course and outcomes of idiopathic pulmonary fibrosis patients in a real-world clinical setting Source: International Congress 2014 – ILDs 6 Year: 2014 Epidemiology of Idiopathic Pulmonary Fibrosis in Australia Source: Virtual Congress 2021 – Interstitial lung disease around the world Year: 2021 Nintedanib in Idiopathic Pulmonary Fibrosis: a single-centre real-life experience Source: International Congress 2017 – IPF: from the bench to the bedside Year: 2017